Cargando…
A patient-derived organoid-based study identified an ASO targeting SNORD14E for endometrial cancer through reducing aberrant FOXM1 Expression and β-catenin nuclear accumulation
BACKGROUND: Most of the endometrial cancer (EC) patients are diagnosis in early stage with a good prognosis while the patients with locally advanced recurrent or metastatic result in a poor prognosis. Adjuvant therapy could benefit the prognosis of patients with high-risk factors. Unfortunately, the...
Autores principales: | Chen, Xi, Liu, Xin, Li, Qian-hui, Lu, Bing-feng, Xie, Bu-min, Ji, Yu-meng, Zhao, Yang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10478245/ https://www.ncbi.nlm.nih.gov/pubmed/37667311 http://dx.doi.org/10.1186/s13046-023-02801-2 |
Ejemplares similares
-
β-Catenin mutations and aberrant nuclear expression during endometrial tumorigenesis
por: Saegusa, M, et al.
Publicado: (2001) -
A three-snoRNA signature: SNORD15A, SNORD35B and SNORD60 as novel biomarker for renal cell carcinoma
por: Zhang, Yue, et al.
Publicado: (2023) -
Phylogenetic Analysis of the SNORD116 Locus
por: Kocher, Matthew A., et al.
Publicado: (2017) -
SNORD63 and SNORD96A as the non-invasive diagnostic biomarkers for clear cell renal cell carcinoma
por: Shang, Xiaoling, et al.
Publicado: (2021) -
P839: GAIN OF CHROMOSOME 1Q LEADS TO HIGH EXPRESSION OF SNORD78 AND ABERRANT RIBOSOME METHYLATION
por: Zhao, Duoduo, et al.
Publicado: (2023)